Alopecia areata continues to be a challenging condition to treat for many patients. Recently, there have been some significant developments with potentially dramatic impact in helping patients with the most severe cases of alopecia areata. Both involve oral medications that affect the immune system and therefore have potential side effects associated with them. Currently, there are clinical trials underway to see whether or not topical treatments can be as effective with less potential side effects. We hope to see positive results in the near future.
You Might Also Enjoy...
These are the first two CME articles on hair transplantation to ever be published in the leading peer reviewed journal in our field. I am proud to be one of its authors.
During the American Academy of Dermatology (AAD) virtual meeting experience, I was happy to participate in this very informative session on innovative therapeutic tools to slow hair loss and increase hair growth.
JAK inhibitors approved now by the FDA represent an important new treatment option for our patients with widespread alopecia areata.
More promising news in the treatment of alopecia areata. More clinical trials are needed to ensure safety and efficacy but very promising.
This analysis demonstrates that there is no increased risk of cancer when using spironolactone.
For some highly motivated patients, a combination of two therapies can be effective in helping hair loss.
